A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07283640
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Blinatumomab
  • KMT2A-rearranged
  • Lymphoblastic Leukemia
  • Revumenib

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Revumenib — DRUG
    Given by po
  • Blinatumomab — DRUG
    Given by IV

Study Details

To learn about the safety and effects of revumenib in combination with blinatumomab in patients with newly diagnosed or relapsed/refractory Ph-negative ALL with a KMT2A rearrangement.

Key Dates

Start date
May 18, 2026
Status verified
Dec 2025
Primary completion
Aug 31, 2029
Completion
Aug 31, 2031

Study Design

Enrollment
20 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1
    Treatment with SC Blinatumomab + Revumenib in R/R ALL
  • Experimental: Cohort 2
    Treatment with SC Blinatumomab + Revumenib in Newly Diagnosed ALL

Primary Outcome Measure

Safety and adverse events (AEs). [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson CancerHoustonTexas77030
Elias J Jabbour, MD
[email protected]
713-792-4764
Elias J Jabbour, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
MD Anderson Cancer· Houston, TX

Related Studies